
浏览全部资源
扫码关注微信
南京中医药大学 中医学院,中西医结合学院,南京 210046
顾俊菲,博士,讲师,从事中药药性理论及复方配伍机制研究,E-mail:gujunfei@njucm.edu.cn
* 唐德才,博士,教授,从事中药药性、配伍机制及应用研究,Tel:025-85811727,E-mail:talknow@njucm.edu.cn
收稿日期:2021-06-27,
网络出版日期:2021-08-20,
纸质出版日期:2021-11-05
移动端阅览
顾俊菲,孙若岚,刘夫艳等.黄芪-莪术配伍对结肠癌原位移植瘤模型小鼠SDF-1/CXCR4/NF-κB信号通路的影响[J].中国实验方剂学杂志,2021,27(21):63-72.
GU Jun-fei,SUN Ruo-lan,LIU Fu-yan,et al.Effect of Astragali Radix-Curcumae Rhizoma on SDF-1/CXCR4/NF-κB Signaling Pathway of Orthotopic Transplantation Model of Colon Cancer in Mice[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(21):63-72.
顾俊菲,孙若岚,刘夫艳等.黄芪-莪术配伍对结肠癌原位移植瘤模型小鼠SDF-1/CXCR4/NF-κB信号通路的影响[J].中国实验方剂学杂志,2021,27(21):63-72. DOI: 10.13422/j.cnki.syfjx.20212023.
GU Jun-fei,SUN Ruo-lan,LIU Fu-yan,et al.Effect of Astragali Radix-Curcumae Rhizoma on SDF-1/CXCR4/NF-κB Signaling Pathway of Orthotopic Transplantation Model of Colon Cancer in Mice[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(21):63-72. DOI: 10.13422/j.cnki.syfjx.20212023.
目的
2
探讨黄芪-莪术抑制结肠癌原位移植瘤模型小鼠肿瘤生长的可能作用机制。
方法
2
运用分子对接技术预测黄芪、莪术中主要活性成分与通路靶点蛋白基质细胞衍生因子-1(SDF-1),趋化因子受体4(CXCR4),核转录因子-
κ
B p65(NF-
κ
B p65)的分子间相互作用。建立CT26.WT结肠癌原位移植瘤模型进行体内实验验证。将60只BALB/c雄性小鼠随机分为假手术组,模型组,5-氟尿嘧啶(5-Fu)组、黄芪-莪术低、中、高剂量组,每组10只。假手术组和模型组给予生理盐水灌胃,5-Fu组(30 mg·kg
-1
)腹腔注射,黄芪-莪术低、中、高剂量组(0.32,0.64,1.28 g·kg
-1
)灌胃。干预15 d后,完整剥离原位瘤,取肿瘤相邻结肠组织5~6 cm。测量并计算肿瘤体积,苏木素-伊红(HE)染色观察肿瘤组织及结肠组织病理学变化,蛋白免疫印迹法(Western blot)检测结肠组织中趋化因子SDF-1及其受体CXCR4,磷酸化NF-
κ
B p65(p-NF-
κ
B p65)蛋白表达,Western blot和实时荧光定量聚合酶链式反应(Real-time PCR)检测肿瘤组织趋化因子SDF-1及其受体CXCR4,NF-
κ
B p65,细胞周期蛋白D
1
(Cyclin D
1
),癌基因c-Myc蛋白及mRNA表达水平。
结果
2
与模型组比较,5-Fu与黄芪-莪术治疗均能降低原位瘤体积(
P
<
0.05,
P
<
0.01),5-Fu组抑瘤率最高(61.38±2.34)%,黄芪-莪术中剂量组抑瘤率(43.43±3.71)%。与模型组比较,各药物组肿瘤与结肠组织的病理学改变转轻。与模型组比较,黄芪-莪术显著下调了肿瘤小鼠结肠组织SDF-1,CXCR4,p-NF-
κ
B p65蛋白表达水平(
P
<
0.01),对肿瘤组织SDF-1,CXCR4,NF-
κ
B p65,Cyclin D
1
,c-Myc的蛋白及mRNA表达明显下调(
P
<
0.05,
P
<
0.01)。
结论
2
黄芪-莪术能够抑制结肠癌原位移植瘤的生长,其干预机制可能与调节SDF-1/CXCR4/NF-
κ
B信号通路中相关蛋白及其mRNA表达有关。
Objective
2
To explore the possible mechanism of Astragali Radix-Curcumae Rhizoma (AC) in inhibiting tumor growth in the orthotopic transplantation model of colon cancer in mice.
Method
2
The molecular docking technology was used to predict the intermolecular interaction between the main active components of AC and the pathway target proteins, such as stromal cell-derived factor-1 (SDF-1), C-X-C motif chemokine receptor 4 (CXCR4), and nuclear factor kappa-B p65 (NF-
κ
B p65). The orthotopic transplantation model of CT26.WT colon cancer was established in mice for
in vivo
experimental verification. Sixty BALB/c male mice were randomly divided into a sham operation group, a model group, a 5-fluorouracil (5-Fu, 30 mg·kg
-1
) group,and low- (0.32 g·kg
-1
), medium- (0.64 g·kg
-1
), and high-dose (1.28 g·kg
-1
) AC groups, with 10 mice in each group. The sham operation group and the model group received normal saline by gavage. The corresponding drugs were administered by gavage in the 5-Fu group and by intraperitoneal injection in the AC groups. After intervention for 15 days, the tumor
in situ
was completely stripped, and the colon tissues 5-6 cm in length adjacent to the tumor were taken. The tumor volume was measured and calculated. The pathological changes of tumor tissues and colon tissues were observed by Hematoxylin-Eosin (HE) staining. Western blot was used to detect the protein expression of SDF-1, CXCR4, p-NF-
κ
B p65 in colon tissues. Western blot and Real-time quantitative polymerase chain reaction (Real-time PCR) were used to detect SDF-1, CXCR4, NF-
κ
B p65, Cyclin D
1
, oncogene c-Myc protein and mRNA expression in tumor tissues.
Result
2
Compared with the model group, 5-Fu and AC groups showed reduced tumor volumes
in situ
(
P
<
0.05,
P
<
0.01), with the tumor inhibition rate in the 5-Fu group as high as (61.38±2.34)%. The tumor-inhibiting effect was optimal in the medium-dose AC group, with the tumor inhibition rate of (43.43±3.71)%. Compared with the model group, 5-Fu and AC groups showed relieved pathological changes of tumor and colon tissues. Specifically, AC down-regulated the protein expression levels of SDF-1, CXCR4, and p-NF-
κ
B p65 in colon tissues (
P
<
0.01), and down-regulated the protein and mRNA expression levels of SDF-1, CXCR4, NF-
κ
B p65, Cyclin D
1
, and c-Myc in tumor tissues (
P
<
0.05,
P
<
0.01).
Conclusion
2
AC can inhibit the growth of orthotopic transplantation tumor of colon cancer, and its intervention mechanism may be related to the regulation of related protein and mRNA expression in the SDF-1/CXCR4/NF-
κ
B signaling pathway.
BRAY F , FERLAY J , SOERJOMATARAM I , et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2018 , 68 ( 6 ): 394 - 424 .
ZHU J , TAN Z , HOLLIS-HANSEN K , et al . Epidemiological trends in colorectal cancer in China: an ecological study [J]. Dig Dis Sci , 2017 , 62 ( 1 ): 235 - 243 .
李华 . 中药活血化瘀在防治恶性肿瘤术后复发与转移中的应用效果 [J]. 黑龙江中医药 , 2020 , 49 ( 2 ): 118 - 119 .
戴文涛 , 王浩华 , 赵春娥 . 大承气汤直肠滴入联合中药封包外敷促进结肠癌术后胃肠道功能恢复的临床研究 [J]. 甘肃科技 , 2020 , 36 ( 15 ): 116 - 118 .
SUN R , GU J , CHANG X , et al . Metabonomics study on orthotopic transplantion mice model of colon cancer treated with Astragalus membranaceus - Curcuma wenyujin in different proportions via UPLC-Q-TOF/MS [J]. J Pharm Biomed Anal , 2021 , doi: 10.1016/j.jpba.2020.113708 http://dx.doi.org/10.1016/j.jpba.2020.113708 .
孙若岚 , 唐德才 , 顾俊菲 . 黄芪-莪术配伍对结肠癌原位移植瘤小鼠模型抗结肠癌生长转移的干预效应研究 [J]. 中国中药杂志 , 2021 , 46 ( 9 ): 2267 - 2275 .
唐德才 . 活血化瘀药在抗肿瘤及转移中的运用思考 [J]. 南京中医药大学学报 , 2019 , 35 ( 1 ): 1 - 4 .
XU C , ZHAO H , CHEN H , et al . CXCR4 in breast cancer: oncogenic role and therapeutic targeting [J]. Drug Des Devel Ther , 2015 , doi: 10.2147/DDDT.S84932 http://dx.doi.org/10.2147/DDDT.S84932 .
GANGADHAR T , NANDI S , SALGIA R . The role of chemokine receptor CXCR4 in lung cancer [J]. Cancer Biol Ther , 2010 , 9 ( 6 ): 409 - 416 .
HUANG Y C , HSIAO Y C , CHEN Y J , et al . Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells [J]. Biochem Pharmacol , 2007 , 74 ( 12 ): 1702 - 1712 .
KONG L , GUO S , LIU C , et al . Overexpression of SDF-1 activates the NF- κ B pathway to induce epithelial to mesenchymal transition and cancer stem cell-like phenotypes of breast cancer cells [J]. Int J Oncol , 2016 , 48 ( 3 ): 1085 - 1094 .
TROTT O , OLSON A J . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading [J]. J Comput Chem , 2010 , 31 ( 2 ): 455 - 461 .
WANG J , CHEN C , WANG S Y , et al . Bufalin inhibits HCT116 colon cancer cells and its orthotopic xenograft tumor in mice model through genes related to apoptotic and PTEN/AKT pathways [J]. Gastroent Res Pract , 2015 , doi: 10.1155/2015/457193 http://dx.doi.org/10.1155/2015/457193 .
JACKSTADT R , SANSOM O J . Mouse models of intestinal cancer [J]. J Pathol , 2016 , 238 ( 2 ): 141 - 151 .
YIN G , CHENG X , TAO W , et al . Comparative analysis of multiple representative components in the herb pair Astragali Radix-Curcumae Rhizoma and its single herbs by UPLC-QQQ-MS [J]. J Pharm Biomed Anal , 2018 , doi: 10.1016/j.jpba.2017.09.015 http://dx.doi.org/10.1016/j.jpba.2017.09.015 .
刘宗超 , 李哲轩 , 张阳 , 等 . 2020全球癌症统计报告解读 [J]. 肿瘤综合治疗电子杂志 , 2021 , 7 ( 2 ): 1 - 14 .
吴幸冬 , 唐德才 . 黄芪配伍莪术对小鼠结肠癌细胞CT26黏附和迁移能力的影响 [J]. 中医杂志 , 2020 , 61 ( 13 ): 1176 - 1183 .
PAVLASOVA G , BORSKY M , SEDA V , et al . Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis [J]. Blood , 2016 , 128 ( 12 ): 1609 - 1613 .
ZHENG H , FU G , DAI T , et al . Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway [J]. J Cardiovasc Pharmacol , 2007 , 50 ( 3 ): 274 - 280 .
CHIRILLO R , AVERSA I , VITO A D , et al . FtH-Mediated ROS dysregulation promotes CXCL12/CXCR4 axis activation and EMT-Like trans-differentiation in erythroleukemia K562 cells [J]. Front Oncol , 2020 , doi: 10.3389/fonc.2020.00698 http://dx.doi.org/10.3389/fonc.2020.00698 .
IERANÒ C , SANTAGATA S , NAPOLITANO M , et al . CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells [J]. Cell Death Dis , 2014 , 5 ( 7 ): e1310 .
CARTWRIGHT T , PERKINS N D , L WILSON C . NFKB1: a suppressor of inflammation, ageing and cancer [J]. FEBS J , 2016 , 283 ( 10 ): 1812 - 1822 .
GONG J , SONG Y , XU L , et al . Upregulation of serine proteinase inhibitor clade B member 3 (SERPINB3) expression by stromal cell-derived factor (SDF-1)/CXCR4/nuclear factor kappa B (NF- κ B) promotes migration and invasion of gastric cancer cells [J]. Med Sci Monit , 2020 , doi: 10.12659/MSM.927411 http://dx.doi.org/10.12659/MSM.927411 .
LIN Y , MA Q , LI L , et al . The CXCL12-CXCR4 axis promotes migration, invasiveness, and EMT in human papillary thyroid carcinoma B-CPAP cells via NF- κ B signaling [J]. Biochem Cell Biol , 2018 , 96 ( 5 ): 619 - 626 .
QIE S , DIEHL J A . Cyclin D 1 , cancer progression, and opportunities in cancer treatment [J]. J Mol Med (Berl) , 2016 , 94 ( 12 ): 1313 - 1326 .
LIU W T , YANG Y , HE B C , et al . ESM1 promotes triple-negative breast cancer cell proliferation through activating Akt/NF- κ B/cyclin D 1 pathway [J]. Ann Transl Med, 2021 , 9 ( 7 ): 533 - 550 .
KOLAPALLI S P , SAHU R , CHAUHAN N R , et al . RNA-binding RING E3-ligase DZIP3/hRUL138 stabilizes cyclin D 1 to drive cell-cycle and cancer progression [J]. Cancer Res , 2021 , 81 ( 2 ): 315 - 331 .
BORZI C , CALZOLARI L , FERRETTI A M , et al . C-Myc shuttled by tumour-derived extracellular vesicles promotes lung bronchial cell proliferation through miR-19b and miR-92a [J]. Cell Death Dis , 2019 , 10 ( 10 ): 759 - 771 .
TANG J , YAN T , BAO Y , et al . LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc [J]. Nat Commun , 2019 , 10 ( 1 ): 3499 - 3513 .
ZHOU W , GUO S , LIU M , et al . Targeting CXCL12/CXCR4 axis in tumor immunotherapy [J]. Curr Med Chem , 2019 , 26 ( 17 ): 3026 - 3041 .
0
浏览量
18
下载量
9
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621